Cost-Effectiveness Analysis of Daclizumab Beta In The Treatment of Relapsing Remitting Multiple Sclerosis In Italy
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.1947
https://www.valueinhealthjournal.com/article/S1098-3015(17)32281-7/fulltext
Title :
Cost-Effectiveness Analysis of Daclizumab Beta In The Treatment of Relapsing Remitting Multiple Sclerosis In Italy
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)32281-7&doi=10.1016/j.jval.2017.08.1947
First page :
A723
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
1774